A comprehensive pooled analysis further reveals a PFS of 7.1 months and an OS of 13.6 months in HER2-mutated non-small cell lung cancer patients with brain metastases (Li et al., 2023). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.